Payment overview · 2025
General Payments
$242,471.53
212 reported records · 20 companies
Healthcare provider profile · identity verified
Brandon Daniel Ayres, MD
Allopathic & Osteopathic Physicians|Ophthalmology · BALA CYNWYD, PA · NPI 1710985460
Verified facts
What the public records show
CMS Open Payments records show Brandon Daniel Ayres, MD received $242,471.53 in general payments during 2025 across 212 reported records.
Alcon Vision LLC accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Miebo, Xdemvy, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lumigan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Simbrinza as an associated drug or biological on 1563 records involving 637 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Simbrinza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xiidra by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FLAREX as an associated drug or biological on 39 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Flarex by this doctor in 2024.
Tarsus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XDEMVY as an associated drug or biological on 46638 records involving 15254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xdemvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $73,524.49 | 30.3% | 44 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $43,342.61 | 17.9% | 46 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39,294.99 | 16.2% | 26 | 2025 |
| Sight Sciences, Inc. | Unresolved — no canonical attribution shown | $32,453.94 | 13.4% | 29 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $13,686.15 | 5.6% | 16 | 2025 |
| LENSAR, Inc. | Unresolved — no canonical attribution shown | $12,000.00 | 5.0% | 2 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $8,918.69 | 3.7% | 9 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $5,461.14 | 2.2% | 15 | 2025 |
| Carl Zeiss Meditec USA, Inc. | Unresolved — no canonical attribution shown | $4,981.05 | 2.0% | 3 | 2025 |
| Alcon Research LLC | Unresolved — no canonical attribution shown | $4,097.85 | 1.7% | 4 | 2025 |
| Microsurgical Technology, Inc. | Unresolved — no canonical attribution shown | $2,500.00 | 1.0% | 1 | 2025 |
| Carl Zeiss Meditec, Inc. | Unresolved — no canonical attribution shown | $838.00 | 0.3% | 2 | 2025 |
| OCULUS, Inc. | Unresolved — no canonical attribution shown | $750.00 | 0.3% | 1 | 2025 |
| Beaver-Visitec International, Inc. | Unresolved — no canonical attribution shown | $179.05 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.50 | 0.1% | 1 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $105.83 | 0.0% | 4 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $69.54 | 0.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $67.49 | 0.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.52 | 0.0% | 3 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $15.69 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $87,612.50 | 38 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,169.24 | 26 |
| Compensation for serving as faculty or as a speaker for a medical education program | $51,177.50 | 16 |
| Travel and Lodging | $12,302.81 | 27 |
| Food and Beverage | $6,459.48 | 104 |
| Honoraria | $750.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $43,028.35 | 40 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $42,864.65 | 36 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $40,108.81 | 14 | 2025 |
Source payment records
|
|||||
| OMNI SURGICAL SYSTEM Normalized: omni surgical system |
Device | Sight Sciences, Inc. | $32,453.94 | 29 | 2025 |
Source payment records
|
|||||
| SION SURGICAL INSTRUMENT Normalized: sion surgical instrument |
Device | Sight Sciences, Inc. | $32,320.50 | 28 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $31,155.65 | 21 | 2025 |
Source payment records
|
|||||
| Clareon Normalized: clareon |
Device | Alcon Research LLC, Alcon Vision LLC | $20,358.67 | 10 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $13,686.15 | 16 | 2025 |
Source payment records
|
|||||
| LENSAR LASER SYSTEM Normalized: lensar laser system |
Device | LENSAR, Inc. | $12,000.00 | 2 | 2025 |
Source payment records
|
|||||
| AcrySof IQ PanOptix UV IOL Normalized: acrysof iq panoptix uv iol |
Device | Alcon Research LLC, Alcon Vision LLC | $8,000.00 | 8 | 2025 |
Source payment records
|
|||||
| QUATERA 700 Normalized: quatera 700 |
Device | Carl Zeiss Meditec USA, Inc., Carl Zeiss Meditec, Inc. | $5,600.00 | 2 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,461.14 | 15 | 2025 |
Source payment records
|
|||||
| VERACITY SURGICAL Normalized: veracity surgical |
Device | Carl Zeiss Meditec USA, Inc. | $4,926.44 | 2 | 2025 |
Source payment records
|
|||||
| AcrySof IQ VIVITY Normalized: acrysof iq vivity |
Device | Alcon Research LLC, Alcon Vision LLC | $4,800.00 | 5 | 2025 |
Source payment records
|
|||||
| Cataract Suite Normalized: cataract suite |
Device | Carl Zeiss Meditec USA, Inc. | $4,800.00 | 1 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $4,700.00 | 3 | 2025 |
Source payment records
|
|||||
| UNITY Normalized: unity |
Device | Alcon Vision LLC | $3,000.00 | 1 | 2025 |
Source payment records
|
|||||
| AcrySof Toric Aspheric UV Absorbing IOL Normalized: acrysof toric aspheric uv absorbing iol |
Device | Alcon Vision LLC | $2,100.00 | 3 | 2025 |
Source payment records
|
|||||
| Centurion Normalized: centurion |
Device | Alcon Research LLC | $2,000.00 | 2 | 2025 |
Source payment records
|
|||||
| Travoprost Intraocular Implant - iDose Normalized: travoprost intraocular implant idose |
Drug | Glaukos Corporation | $1,699.47 | 2 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec, Inc. | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| CIRRUS HD-OCT Normalized: cirrus hd oct |
Device | Carl Zeiss Meditec, Inc. | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| VisuMax Normalized: visumax |
Device | Carl Zeiss Meditec, Inc. | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| Pentacam Normalized: pentacam |
Device | OCULUS, Inc. | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| LenSx Normalized: lensx |
Device | Alcon Vision LLC | $700.00 | 1 | 2025 |
Source payment records
|
|||||
| KXL system (not refurbished) Normalized: kxl system not refurbished |
Device | Glaukos Corporation | $196.33 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $175.84 | 4 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $175.76 | 3 | 2025 |
Source payment records
|
|||||
| STELLARIS Normalized: stellaris |
Device | Bausch & Lomb Americas Inc. | $144.69 | 2 | 2025 |
Source payment records
|
|||||
| enVista Aspire IOL Normalized: envista aspire iol |
Device | Bausch & Lomb Americas Inc. | $144.69 | 2 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $144.69 | 2 | 2025 |
Source payment records
|
|||||
| XIPERE Normalized: xipere |
Drug | Bausch & Lomb Americas Inc. | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $135.39 | 2 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $124.50 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $67.49 | 2 | 2025 |
Source payment records
|
|||||
| LUMERA 700 Normalized: lumera 700 |
Device | Carl Zeiss Meditec USA, Inc. | $54.61 | 1 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $54.08 | 2 | 2025 |
Source payment records
|
|||||
| IOLMaster 700 Normalized: iolmaster 700 |
Device | Carl Zeiss Meditec, Inc. | $38.00 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $33.99 | 1 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| ILUVIEN Normalized: iluvien |
Drug | ANI Pharmaceuticals, Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MIEBO miebo |
2025 | Miebo | 2024 | 80 | exact normalized | Medicare Part D |
| XDEMVY xdemvy |
2025 | Xdemvy | 2024 | 20 | exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Simbrinza open payments reported associated product |
CMS Open Payments — General Payments 1563 supporting records · 637 recipient NPIs · example record 1207357100 |
Simbrinza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
39 | 18 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
80 | 28 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | FLAREX open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 37 recipient NPIs · example record 1236210819 |
Flarex · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Tarsus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XDEMVY open payments reported associated product |
CMS Open Payments — General Payments 46638 supporting records · 15254 recipient NPIs · example record 1233825434 |
Xdemvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 1156 | 439 |
| Ofloxacin | Ofloxacin | 329 | 195 |
| Loteprednol Etabonate | Loteprednol Etabonate | 266 | 107 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 130 | 48 |
| Valacyclovir | Valacyclovir Hcl | 117 | 33 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 91 | 37 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 84 | 59 |
| Cyclosporine | Cyclosporine | 82 | 39 |
| Miebo | Perfluorohexyloctane/Pf | 80 | 28 |
| Latanoprost | Latanoprost | 78 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 50 |
| Cyclopentolate Hcl | Cyclopentolate Hcl | 73 | 58 |
| Restasis | Cyclosporine | 60 | 32 |
| Moxifloxacin | Moxifloxacin Hcl | 58 | 20 |
| Brimonidine Tartrate | Brimonidine Tartrate | 57 | 19 |
| Difluprednate | Difluprednate | 53 | 21 |
| Timolol Maleate | Timolol Maleate | 52 | 20 |
| Fluorometholone | Fluorometholone | 41 | 21 |
| Lotemax Sm | Loteprednol Etabonate | 39 | 18 |
| Acyclovir | Acyclovir | 31 | 11 |
| Erythromycin | Erythromycin Base | 31 | 19 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 25 | 11 |
| Lumigan | Bimatoprost | 25 | suppressed |
| Xiidra | Lifitegrast | 25 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 21 | 12 |
| Xdemvy | Lotilaner | 20 | 20 |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 18 | 11 |
| Besivance | Besifloxacin Hcl | 18 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 18 | suppressed |
| Alphagan P | Brimonidine Tartrate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Cosopt Pf | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Tyrvaya | Varenicline Tartrate | 12 | suppressed |
| Flarex | Fluorometholone Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $242,471.53 · 212 records | Alcon Vision LLC | ACTHAR, AcrySof IQ PanOptix UV IOL, AcrySof IQ VIVITY, AcrySof Toric Aspheric UV Absorbing IOL, CALLISTO eye, CIRRUS HD-OCT, Cataract Suite, Centurion, Cequa, Clareon, Clareon PanOptix Pro, IHEEZO, ILUVIEN, IOLMaster 700, KXL System, KXL system (not refurbished), LENSAR LASER SYSTEM, LUMERA 700, LenSx, MIEBO, OMNI SURGICAL SYSTEM, OXERVATE, PURIFIED CORTROPHIN GEL, Pentacam, Photrexa Viscous and Photrexa, QUATERA 700, SION SURGICAL INSTRUMENT, STELLARIS, TECNIS IOL, TRYPTYR, Travoprost Intraocular Implant - iDose, UNITY, VERACITY SURGICAL, VEVYE, VYZULTA, VisuMax, XDEMVY, XEN GLAUCOMA TREATMENT SYSTEM, XIIDRA, XIPERE, enVista Aspire IOL, enVista Envy IOL, enVista MX60 IOL | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Miebo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error